638
Participants
Start Date
June 30, 2005
Primary Completion Date
November 30, 2006
Study Completion Date
June 30, 2013
dasatinib
Tablets, Oral, 70 mg BID, indefinitely, survival study
dasatinib
Tablets, Oral, 140 mg QD, indefinitely, survival study
Local Institution, Jesus Maria
Local Institution, Lima
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Brussels
Local Institution, Vienna
Local Institution, Quezon City
Local Institution, Budapest
Local Institution, Capital Federal
Local Institution, St Leonards
Local Institution, Parktown
Local Institution, Herlev
Local Institution, B-leuven
Local Institution, Parkville
Local Institution, Basel
Local Institution, South Brisbane
Local Institution, Odense C
Local Institution, Yvoir
Local Institution, Charleroi
Local Institution, Trondheim
Local Institution, Observatory
Local Institution, Bruges
Local Institution, Aarhus C
Local Institution, Bloemfontein
New York Presbyterian Hospital, New York
Local Institution, Orbassano (to)
Local Institution, Bangkok
Local Institution, Athens
Local Institution, Marseille
Local Institution, Caen
Western Pennsylvania Cancer Institute, Pittsburgh
Local Institution, Stockholm
Washington Cancer Institute At Washington Hospital Center, Washington D.C.
Local Institution, Monza
Local Institution, Hamburg
Local Institution, Lublin
Local Institution, Lund
Local Institution, Madrid
Local Institution, Madrid
Emory University School Of Medicine, Atlanta
Local Institution, Krakow
University Of Miami, Miami
Local Institution, Pessac
University Of Alabama At Birmingham, Birmingham
Sarah Cannon Research Institute, Nashville
Local Institution, Grenoble
Local Institution, Katowice
Local Institution, Bologna
Local Institution, Nantes
Cleveland Clinic Foundation, Cleveland
Local Institution, Valencia
Indiana University Cancer Center, Indianapolis
Karmanos Cancer Center, Detroit
Local Institution, Ramat Gan
Local Institution, Mainz
Local Institution, Lille
Local Institution, Frankfurt
Northwestern University, Chicago
Local Institution, Brno
Local Institution, Strasbourg
Nebraska Methodist Hospital, Omaha
Local Institution, Mannheim
Local Institution, Lyon
Local Institution, Bari
Local Institution, Uppsala
Local Institution, Paris
The University Of Texas Md Anderson Cancer Center, Houston
Local Institution, Napoli
Local Institution, Gdansk
Local Institution, Poitiers
Ucla Dept. Of Medicine, Los Angeles
Local Institution, Umeå
Loma Linda University Cancer Center, Loma Linda
Local Institution, Lodz
Local Institution, Créteil
Oregon Health & Sci Univ, Portland
Seattle Cancer Care Alliance, Seattle
Local Institution, Moscow
Local Institution, Singapore
Local Institution, Saint Petersburg
The University Of Chicago, Chicago
University Of Kentucky, Lexington
University Of Maryland, Baltimore
Dana Faber Cancer Institute, Boston
Washington University School Of Medicine, St Louis
Devetten, Marcel, Omaha
The Cancer Center At Hackensack University Medical Center, Hackensack
The Cancer Institute Of New Jersey, New Brunswick
The University Of North Carolina At Chapel Hill, Chapel Hill
Local Institution, Adelaide
Local Institution, Perth
Local Institution, Curitiba
Local Institution, Campinas
Local Institution, Morumbi
Local Institution, São Paulo
Local Institution, Rio de Janeiro
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Montreal
Local Institution, Prague
Local Institution, Helsinki
Local Institution, Dresden
Local Institution, Leipzig
Local Institution, Dublin
Local Institution, Jeollanam-do
Local Institution, Taipei
Local Institution, Roma
Local Institution, Rotterdam
Local Institution, Warsaw
Local Institution, Groenkloof
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Barcelona
Local Institution, London
Local Institution, Glasgow
Local Institution, Newcastle
Local Institution, Edinburgh
Local Institution, Liverpool
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY